Year: 2023
Type: editorial
Abstract: The adjuvant anti-PD-L1 MAb atezolizumab (Tecentriq) combined with anti-VEGF-A bevacizumab (Avastin, both Genentech) extended recurrence-free survival by 28%, compared to active surveillance, in he...
Authors: Ronald Ellis, Adam Weiss
Institution: Taylor and Francis (United Kingdom)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,175
OpenAlex ID: W4376640917